TY  - JOUR
AU  - Soch, Joram
AU  - Richter, Anni
AU  - Kizilirmak, Jasmin M
AU  - Schütze, Hartmut
AU  - Ziegler, Gabriel
AU  - Altenstein, Slawek
AU  - Brosseron, Frederic
AU  - Dechent, Peter
AU  - Fliessbach, Klaus
AU  - Freiesleben, Silka Dawn
AU  - Glanz, Wenzel
AU  - Gref, Daria
AU  - Heneka, Michael
AU  - Hetzer, Stefan
AU  - Incesoy, Enise I
AU  - Kilimann, Ingo
AU  - Kimmich, Okka
AU  - Kleineidam, Luca
AU  - Kuhn, Elizabeth
AU  - Laske, Christoph
AU  - Lohse, Andrea
AU  - Lüsebrink, Falk
AU  - Munk, Matthias H
AU  - Peters, Oliver
AU  - Preis, Lukas
AU  - Priller, Josef
AU  - Ramirez, Alfredo
AU  - Roeske, Sandra
AU  - Rostamzadeh, Ayda
AU  - Roy-Kluth, Nina
AU  - Scheffler, Klaus
AU  - Schmid, Matthias
AU  - Schneider, Anja
AU  - Spottke, Annika
AU  - Spruth, Eike Jakob
AU  - Teipel, Stefan
AU  - Wiltfang, Jens
AU  - Jessen, Frank
AU  - Wagner, Michael
AU  - Düzel, Emrah
AU  - Schott, Björn H
TI  - Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.
JO  - Brain
VL  - 147
IS  - 11
SN  - 0006-8950
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DZNE-2024-01303
SP  - 3789 - 3803
PY  - 2024
AB  - Single-value scores reflecting the deviation from (FADE score) or similarity with (SAME score) prototypical novelty-related and memory-related functional MRI activation patterns in young adults have been proposed as imaging biomarkers of healthy neurocognitive ageing. Here, we tested the utility of these scores as potential diagnostic and prognostic markers in Alzheimer's disease (AD) and risk states like mild cognitive impairment (MCI) or subjective cognitive decline (SCD). To this end, we analysed subsequent memory functional MRI data from individuals with SCD, MCI and AD dementia as well as healthy controls and first-degree relatives of AD dementia patients (AD-rel) who participated in the multi-centre DELCODE study (n = 468). Based on the individual participants' whole-brain functional MRI novelty and subsequent memory responses, we calculated the FADE and SAME scores and assessed their association with AD risk stage, neuropsychological test scores, CSF amyloid positivity and APOE genotype. Memory-based FADE and SAME scores showed a considerably larger deviation from a reference sample of young adults in the MCI and AD dementia groups compared to healthy controls, SCD and AD-rel. In addition, novelty-based scores significantly differed between the MCI and AD dementia groups. Across the entire sample, single-value scores correlated with neuropsychological test performance. The novelty-based SAME score further differed between Aβ-positive and Aβ-negative individuals in SCD and AD-rel, and between ApoE ɛ4 carriers and non-carriers in AD-rel. Hence, FADE and SAME scores are associated with both cognitive performance and individual risk factors for AD. Their potential utility as diagnostic and prognostic biomarkers warrants further exploration, particularly in individuals with SCD and healthy relatives of AD dementia patients.
KW  - Humans
KW  - Alzheimer Disease: genetics
KW  - Alzheimer Disease: psychology
KW  - Alzheimer Disease: physiopathology
KW  - Male
KW  - Female
KW  - Aged
KW  - Magnetic Resonance Imaging
KW  - Cognitive Dysfunction: physiopathology
KW  - Brain: diagnostic imaging
KW  - Middle Aged
KW  - Neuropsychological Tests
KW  - Severity of Illness Index
KW  - Adult
KW  - Aged, 80 and over
KW  - Apolipoproteins E: genetics
KW  - Alzheimer’s disease (Other)
KW  - dementia risk (Other)
KW  - fMRI scores (Other)
KW  - mild cognitive impairment (Other)
KW  - novelty processing (Other)
KW  - subsequent memory (Other)
KW  - Apolipoproteins E (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38743817
C2  - pmc:PMC11531847
DO  - DOI:10.1093/brain/awae149
UR  - https://pub.dzne.de/record/272890
ER  -